Low Molecular Weight Heparin Global Market Report 2025
상품코드:1825793
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
저분자량 헤파린 시장 규모는 향후 몇 년 동안 강력한 성장이 예상됩니다. 2029년에는 CAGR 9.1%로 74억 9,000만 달러로 성장할 것입니다. 예측 기간의 성장은 노인 인구 증가, 미분획 헤파린 대비 저분자량 헤파린의 우위 증가, 응고 장애 발생률 증가, 비만 유병률 증가, 전 세계 혈액 질환 유병률 증가에 기인하는 것으로 추정됩니다. 예측 기간의 주요 동향으로는 기술 발전, 맞춤형 의료, 원격의료와의 통합, 웨어러블 기술과의 통합, 전략적 파트너십, 협업 등을 꼽을 수 있습니다.
향후 5년간 9.1%의 성장률 전망은 지난번 예측보다 0.8% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 관세 장벽은 이탈리아나 스페인에서 공급되는 에녹사파린과 항응고 모니터링 장비의 비용을 상승시킴으로써 미국의 병원 처방을 억제하고 혈전증 예방을 저해하며 수술 전후 의료비를 상승시킬 것으로 예상됩니다. 또한, 상호 관세와 무역 긴장과 제한의 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.
혈액 질환의 유병률 증가는 당분간 저분자량 헤파린 시장의 성장을 가속화할 것으로 예상됩니다. 혈액 질환에는 적혈구, 백혈구, 혈소판, 혈장 단백질 등 혈액 성분에 영향을 미치는 다양한 질환이 포함되며, 빈혈, 혈우병, 혈전증 등의 질환이 포함됩니다. 이러한 질환의 발병률 증가 요인으로는 인구 고령화, 진단 기술의 발전, 환경적 위험에 대한 노출 증가 등을 들 수 있습니다. 저분자량 헤파린은 혈전 형성을 억제하는 능력으로 혈전색전증을 예방 및 치료하고 혈액 질환을 관리하는 데 매우 중요합니다. 예를 들어, 백혈병 재단은 2024년 5월, 2022년에는 약 19,403명의 호주인이 백혈병, 림프종, 골수종 등 혈액암 진단을 받을 것으로 예상하고 효과적인 치료에 대한 필요성을 강조한 바 있습니다. 현재 약 135,000명의 호주인이 혈액암 및 혈액질환을 앓고 있으며, 2035년에는 275,000명을 넘어설 것으로 예측됩니다. 따라서 혈액 질환의 유병률 증가는 저분자량 헤파린 시장 확대의 주요 요인으로 작용하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 저분자량 헤파린 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 저분자량 헤파린 시장 : 성장률 분석
세계의 저분자량 헤파린 시장 실적 : 규모와 성장, 2019-2024
세계의 저분자량 헤파린 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 저분자량 헤파린 : 총 잠재 시장 규모(TAM)
제6장 시장 세분화
세계의 저분자량 헤파린 시장 : 제품 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
에녹사파린
달테파린
틴자파린
후라키시파린
나드로파린
기타 제품 유형
세계의 저분자량 헤파린 시장 : 포장별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
멀티 바이알
프리필드 시린지
세계의 저분자량 헤파린 시장 : 용도별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
심부정맥혈전증
급성관상동맥증후군
폐색전증
기타 용도
세계의 저분자량 헤파린 시장 : 하위 세분화 에녹사파린(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
제네릭 에녹사파린
브랜드 이름 에녹사파린
세계의 저분자량 헤파린 시장 : 하위 세분화 달테파린(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
제네릭 달테파린
브랜드 이름 달테파린
세계의 저분자량 헤파린 시장 : 하위 세분화 틴자파린(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
제네릭크틴자파린
브랜드 명 : 틴자파린
세계의 저분자량 헤파린 시장 : 하위 세분화 후라키시파린(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
제네릭크후라키시파린
브랜드 명후라키시파린
세계의 저분자량 헤파린 시장 : 하위 세분화 나드로파린(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
제네릭크나드로파린
브랜드 명 : 나드로파린
세계의 저분자량 헤파린 시장 : 하위 세분화 기타 제품 유형(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
베미파린
파르나파린
제7장 지역별·국가별 분석
세계의 저분자량 헤파린 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 저분자량 헤파린 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
저분자량 헤파린 시장 : 경쟁 구도
저분자량 헤파린 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis
Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
Eisai Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
Sun Pharmaceutical Industries Ltd.
Cipla Inc.
Apotex Inc.
Intas Pharmaceuticals Ltd
Hikma Pharmaceuticals PLC
Dr. Reddy's Laboratories Ltd.
Lupin Limited
Alkem Laboratories Limited
Torrent Pharmaceuticals Ltd.
Emcure Pharmaceuticals Limited
Biocon Limited
Aspen Pharmacare Holdings Limited
Ajanta Pharma Ltd.
Zydus Pharmaceuticals
Gland Pharma Limited
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
저분자량 헤파린 시장 2029 : 새로운 기회를 제공하는 국가
저분자량 헤파린 시장 2029 : 새로운 기회를 제공하는 부문
저분자량 헤파린 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
KSM
영문 목차
영문목차
Low molecular weight heparin (LMWH) is a type of anticoagulant medication derived from standard heparin through chemical or enzymatic depolymerization, resulting in smaller fragments. Its mechanism of action involves inhibiting factor Xa and, to a lesser extent, thrombin, thereby preventing and treating blood clots. LMWHs are preferred over unfractionated heparin due to their more predictable pharmacokinetics, longer half-life, and lower risk of adverse effects such as heparin-induced thrombocytopenia.
Enoxaparin, dalteparin, tinzaparin, fraxiparine, nadroparin, and other variations constitute the main product types of low molecular weight heparin. Enoxaparin, specifically, is utilized for preventing blood clots in conditions such as deep vein thrombosis and pulmonary embolism. Its packaging includes multi-vials and prefilled syringes tailored for various applications, including deep vein thrombosis and acute coronary syndrome.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The low molecular weight heparin research report is one of a series of new reports from The Business Research Company that provides low molecular weight heparin market statistics, including the low molecular weight heparin industry's global market size, regional shares, competitors with a low molecular weight heparin market share, detailed low molecular weight heparin market segments, market trends and opportunities, and any further data you may need to thrive in the low molecular weight heparin industry. This low molecular weight heparin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The low molecular weight heparin market size has grown strongly in recent years. It will grow from $4.85 billion in 2024 to $5.29 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to the increasing introduction of biosimilar low molecular weight heparin anticoagulants globally, increasing prevalence of cardiovascular diseases, demand for anticoagulant therapies, demand for anticoagulant therapies, increasing incidence of thrombosis and embolism.
The low molecular weight heparin market size is expected to see strong growth in the next few years. It will grow to $7.49 billion in 2029 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to the rising geriatric population, increasing advantages of low molecular weight heparin over unfractionated heparin, increasing incidences of coagulation disorders, rise in the prevalence of obesity, and increased prevalence of blood disorders worldwide. Major trends in the forecast period include technological advancements, personalized medicine, telehealth integration, wearable technology integration, strategic partnerships, and collaboration.
The forecast of 9.1% growth over the next five years reflects a modest reduction of 0.8% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper U.S. hospital formularies by increasing the cost of enoxaparin and anticoagulation monitoring devices sourced from Italy and Spain, thereby compromising thrombosis prevention and elevating perioperative care costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The rising prevalence of blood disorders is anticipated to accelerate the growth of the low molecular weight heparin market in the foreseeable future. Blood disorders encompass a spectrum of conditions affecting blood components such as red blood cells, white blood cells, platelets, and plasma proteins, including disorders such as anemia, hemophilia, and thrombosis. Factors contributing to the increased incidence of these disorders include aging populations, advancements in diagnostic techniques, and heightened exposure to environmental risks. Low molecular weight heparin is crucial in managing blood disorders by preventing and treating thromboembolism through its ability to inhibit clot formation. For instance, the Leukemia Foundation reported in May 2024 that an estimated 19,403 Australians are expected to be newly diagnosed with blood cancers such as leukemia, lymphoma, and myeloma in 2022, underscoring a significant need for effective treatments. Currently, approximately 135,000 Australians live with a blood cancer or blood disorder, a number projected to exceed 275,000 by 2035. Therefore, the increasing prevalence of blood disorders is a primary driver behind the expansion of the low molecular weight heparin market.
Leading companies in the low molecular weight heparin market are focusing on innovative solutions, including preservative-free prefilled syringes, to enhance safety and convenience for patients. These syringes come pre-filled with enoxaparin, an anticoagulant medication, and are formulated without preservatives to minimize allergic reactions and ensure safety and efficacy. For example, in June 2023, Techdow USA Inc., a US-based generic injectable company, introduced preservative-free prefilled syringes of generic enoxaparin sodium in various strengths ranging from 30 mg to 150 mg. This initiative aims to improve affordability, efficacy, accessibility, and overall patient care compared to existing options.
In May 2022, Fresenius Kabi AG, a Germany-based provider of IV pumps and solutions, acquired Ivenix Inc. to strengthen its portfolio in the medical technology sector. This strategic acquisition integrates Ivenix's advanced infusion therapy platform, which includes low molecular weight heparin among its offerings, enhancing hospital connectivity and interoperability. Ivenix Inc., based in the US, is recognized for providing innovative solutions in infusion therapy, including low molecular weight heparin (LMWH), to improve patient outcomes.
Major companies operating in the low molecular weight heparin market are Pfizer Inc., Sanofi SA, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Cipla Inc., Apotex Inc., Intas Pharmaceuticals Ltd, Hikma Pharmaceuticals PLC, Dr. Reddy's Laboratories Ltd., Lupin Limited, Alkem Laboratories Limited, Torrent Pharmaceuticals Ltd., Emcure Pharmaceuticals Limited, Biocon Limited, Aspen Pharmacare Holdings Limited, Ajanta Pharma Ltd., Zydus Pharmaceuticals, Gland Pharma Limited, Beximco Pharmaceuticals Ltd
North America was the largest region in the low molecular weight heparin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the low molecular weight heparin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the low molecular weight heparin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The low molecular weight heparin market consists of sales of certoparin, reviparin, and bemiparin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Low Molecular Weight Heparin Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on low molecular weight heparin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for low molecular weight heparin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The low molecular weight heparin market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Product Type: Enoxaparin; Dalteparin; Tinzaparin; Fraxiparine; Nadroparin; Other Product Types
2) By Packaging: Multi-Vials; Prefilled Syringes
3) By Application: Deep Vein Thrombosis; Acute Coronary Syndrome; Pulmonary Embolism; Other Applications
Subsegments:
1) By Enoxaparin: Generic Enoxaparin; Branded Enoxaparin
2) By Dalteparin: Generic Dalteparin; Branded Dalteparin
3) By Tinzaparin: Generic Tinzaparin; Branded Tinzaparin
4) By Fraxiparine: Generic Fraxiparine; Branded Fraxiparine
5) By Nadroparin: Generic Nadroparin; Branded Nadroparin
3. Low Molecular Weight Heparin Market Trends And Strategies
4. Low Molecular Weight Heparin Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Low Molecular Weight Heparin Growth Analysis And Strategic Analysis Framework
5.1. Global Low Molecular Weight Heparin PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Low Molecular Weight Heparin Market Growth Rate Analysis
5.4. Global Low Molecular Weight Heparin Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Low Molecular Weight Heparin Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Low Molecular Weight Heparin Total Addressable Market (TAM)
6.1. Global Low Molecular Weight Heparin Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Enoxaparin
Dalteparin
Tinzaparin
Fraxiparine
Nadroparin
Other Product Types
6.2. Global Low Molecular Weight Heparin Market, Segmentation By Packaging, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Multi-Vials
Prefilled Syringes
6.3. Global Low Molecular Weight Heparin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Deep Vein Thrombosis
Acute Coronary Syndrome
Pulmonary Embolism
Other Applications
6.4. Global Low Molecular Weight Heparin Market, Sub-Segmentation Of Enoxaparin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Generic Enoxaparin
Branded Enoxaparin
6.5. Global Low Molecular Weight Heparin Market, Sub-Segmentation Of Dalteparin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Generic Dalteparin
Branded Dalteparin
6.6. Global Low Molecular Weight Heparin Market, Sub-Segmentation Of Tinzaparin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Generic Tinzaparin
Branded Tinzaparin
6.7. Global Low Molecular Weight Heparin Market, Sub-Segmentation Of Fraxiparine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Generic Fraxiparine
Branded Fraxiparine
6.8. Global Low Molecular Weight Heparin Market, Sub-Segmentation Of Nadroparin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Generic Nadroparin
Branded Nadroparin
6.9. Global Low Molecular Weight Heparin Market, Sub-Segmentation Of Other Product Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Bemiparin
Parnaparin
7. Low Molecular Weight Heparin Market Regional And Country Analysis
7.1. Global Low Molecular Weight Heparin Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Low Molecular Weight Heparin Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
